tiprankstipranks
Advertisement
Advertisement

SE:CANTA Stock Latest News

Cantargia: Buy Rating Reiterated on Strategic Pipeline Progress and Unchanged $14 Price Target
RatingsCantargia: Buy Rating Reiterated on Strategic Pipeline Progress and Unchanged $14 Price Target
5h ago
Cantargia AGM Backs Equity Incentives and Expands Capital Raising Mandate
PremiumCompany Announcements
Cantargia AGM Backs Equity Incentives and Expands Capital Raising Mandate
1d ago
Cantargia Highlights Pipeline Progress in Q1 2026 Interim Report
PremiumCompany Announcements
Cantargia Highlights Pipeline Progress in Q1 2026 Interim Report
4d ago
Cantargia to Present Q1 2026 Interim Results in Audiocast and Teleconference
PremiumCompany Announcements
Cantargia to Present Q1 2026 Interim Results in Audiocast and Teleconference
17d ago
Cantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14
PremiumRatings
Cantargia Reiterated as Buy on Nadunolimab’s Strong Early Data and Pipeline Progress; Price Target Maintained at SEK14
25d ago
Cantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial
PremiumCompany AnnouncementsCantargia Reports Promising Early Remissions with Nadunolimab in High-Risk MDS and AML Trial
26d ago
Cantargia Showcases New Nadunolimab Trial in Hard-to-Treat Colorectal Cancer at AACR 2026
Premium
Company Announcements
Cantargia Showcases New Nadunolimab Trial in Hard-to-Treat Colorectal Cancer at AACR 2026
1M ago
Cantargia convenes 2026 AGM with focus on continuity in board
Premium
Company Announcements
Cantargia convenes 2026 AGM with focus on continuity in board
1M ago
Cantargia Showcases Promising Nadunolimab Data in Hard-to-Treat Colorectal Cancer
PremiumCompany Announcements
Cantargia Showcases Promising Nadunolimab Data in Hard-to-Treat Colorectal Cancer
2M ago
Cantargia to Court Investors at Van Lanschot Kempen Life Sciences Conference
PremiumCompany Announcements
Cantargia to Court Investors at Van Lanschot Kempen Life Sciences Conference
3M ago
Cantargia to Highlight Antibody Platform at TD Cowen Healthcare Conference
PremiumCompany Announcements
Cantargia to Highlight Antibody Platform at TD Cowen Healthcare Conference
3M ago
Cantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside
PremiumRatings
Cantargia: Solid Cash Runway and Expanding Nadunolimab Pipeline Support Buy Rating and Long-Term Upside
3M ago
Cantargia Highlights Pipeline Progress in 2025 Year-End Report
PremiumCompany AnnouncementsCantargia Highlights Pipeline Progress in 2025 Year-End Report
3M ago
Cantargia Sets Date for 2025 Annual Results and Investor Presentation
Premium
Company Announcements
Cantargia Sets Date for 2025 Annual Results and Investor Presentation
4M ago
Cantargia to Engage Investors at Leerink Global Healthcare Conference
Premium
Company Announcements
Cantargia to Engage Investors at Leerink Global Healthcare Conference
4M ago
Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB
PremiumRatings
Expanding Nadunolimab’s Oncology Footprint: Low-Cost MSS-CRC Study De-Risks Pivotal Pancreatic Program and Supports Buy Rating on Cantargia AB
4M ago
Cantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer
PremiumCompany Announcements
Cantargia Begins US Trial of Nadunolimab Combo in Hard-to-Treat Colorectal Cancer
4M ago
Cantargia AB: Strategic Focus on PDAC and Autoimmune Indications Amid TRIFOUR Study Setback
PremiumRatings
Cantargia AB: Strategic Focus on PDAC and Autoimmune Indications Amid TRIFOUR Study Setback
6M ago
Cantargia Reports TRIFOUR Study Results on Nadunolimab
PremiumCompany Announcements
Cantargia Reports TRIFOUR Study Results on Nadunolimab
6M ago
Cantargia AB: Strategic Partnerships and Financial Stability Drive Buy Rating
PremiumRatingsCantargia AB: Strategic Partnerships and Financial Stability Drive Buy Rating
6M ago
Cantargia AB Releases Interim Report Highlighting Strategic Progress
Premium
Company Announcements
Cantargia AB Releases Interim Report Highlighting Strategic Progress
6M ago
Cantargia AB Announces Nomination Committee for 2026 AGM
Premium
Company Announcements
Cantargia AB Announces Nomination Committee for 2026 AGM
6M ago

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >